Jeantet has advised Biogaran, a French pharmaceutical company specialized in generic and biosimilar drugs, and subsidiary of the French biggest pharmaceutical group Servier on the acquisition of Swipha, a Nigerian company that manufactures and distributes pharmaceutical products known for their quality.
This acquisition is an important step forward in internationalization of Biogaran, considering Nigeria as the best entry point on the African continent with its strong population and solid economic fundamentals.
Established in 1976, Swipha was the first pharmaceutical company in Nigeria to attain ISO 9001:2000 certification. Approved by the World Health Organization (WHO) in 2014, Swipha employs 300 people locally and generated record sales of NGN 4bn (approximately € 20 million) in 2012. Beyond its production unit, the company also has a wide distribution network covering most parts of Nigeria.
The Jeantet team was led by partner François d’Ornano and was composed of Anna-Maria Veres, senior associate (M&A practice), assisted by the local law firm, ACAS-Law.